MA16.01 Subsequent Systemic Therapy After Lurbinectedin Discontinuation in Patients With Small-cell Lung Cancer
نویسندگان
چکیده
Lurbinectedin, a selective inhibitor of oncogenic transcription, was approved on June 15, 2020 by the US Food and Drug Administration for treatment adult patients with metastatic small-cell lung cancer (SCLC) disease progression or after platinum-based chemotherapy. Accelerated approval based single-arm, open-label, phase 2 basket trial (NCT02454972). In trial, lurbinectedin achieved 35.2% overall response rate (ORR) 9.3-month median survival (OS).
منابع مشابه
Clinicopathological Features of Patients with Non-small-cell Lung Cancer in West of Iran
Background: Lung cancer is the most common cause of cancer death worldwide with an annual mortality rate of more than 1.3 million worldwide. We aimed to analyze the clinicopathological features of patients with non-small-cell lung cancer (NSCLC) in west of Iran. Methods: 64 patients with NSCLC who referred to our clinic were analyzed. Sex, age, histopathology, location of the tumor, treatment,...
متن کاملSystemic therapy treatment patterns in patients with advanced non‐small cell lung cancer (NSCLC): PIvOTAL study
The aim of this multinational retrospective cohort study, conducted at academic and community oncology centres, was to describe real-world treatment patterns for patients with a confirmed diagnosis of advanced/metastatic (stage IIIB/IV) non-small cell lung cancer (NSCLC) who initiated first-line systemic therapy from January 2011 through June 2014. The study included 1265 patients in Italy, Spa...
متن کاملSystemic Therapy Options for Non–Small-Cell Lung Cancer in Patients with a Poor Performance Status
Discuss appropriate management strategies for patients with advanced non-small cell lung cancer (NSCLC) who have a poor performance status (PS). Explore the role of concurrent chemotherapy for locally advanced NSCLC in patients with a PS of 2. Review the single-agent, doublet, and molecularly targeted therapies under investigation for patients with advanced NSCLC with a poor PS. Appreciate the ...
متن کاملSurvival and Prognostic Factors in Small Cell Lung Cancer Patients in Turkey
Background: Small cell lung cancer (SCLC) is a highly aggressive tumor. Objective: To evaluate the survival and time to progression of patients with SCLC admitted to a chest disease center in Istanbul, Turkey. Methods: Based on the reports of a pulmonary oncology clinic, data regarding performance status (PS), clinical stage of disease, treatment, time to progression and survival of 67 patients...
متن کاملCharacteristics and Prognostic Impact of Pneumonitis during Systemic Anti-Cancer Therapy in Patients with Advanced Non-Small-Cell Lung Cancer
BACKGROUND Data on characteristics, outcomes, and prognosis of advanced non-small-cell lung cancer (NSCLC) patients who develop pneumonitis during systemic anti-cancer therapy (pneumonitis) are currently lacking. METHODS We conducted a retrospective cohort study of 910 consecutive patients diagnosed with advanced NSCLC between January 2004 and January 2014. Of these, 140 patients were exclude...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2021
ISSN: ['1556-0864', '1556-1380']
DOI: https://doi.org/10.1016/j.jtho.2021.08.194